THINX HEALTHCARE Establishes System for Domestic Approval of Botulinum Toxin Preparations

THINX HEALTHCARE Co., Ltd. (Headquarters: Minato-ku, Tokyo; Representative Director: Taishi Todaka; hereinafter "our group"), a consolidated subsidiary of CONVANO Co., Ltd. (Headquarters: Shibuya-ku, Tokyo; Representative Director and President: Aya Kamishimoto; Securities Code: 6574; hereinafter "the Company"), plans to conclude a business consignment agreement with CM Plus Co., Ltd. (hereinafter "CM Plus") to obtain manufacturing and marketing approval for botulinum toxin preparations in Japan.

Through this agreement, our group will establish a specialized support system in the pharmaceutical affairs, quality, and clinical domains necessary for drug approval, aiming to enhance and accelerate the approval acquisition process.

■ Background: Business Expansion in a Growing Market

Botulinum toxin preparations are a field with expanding demand in both aesthetic medicine and therapeutic areas. In the global market, these preparations form a market worth approximately 6 billion USD annually, with continued growth expected.

Our group positions this area as a high-value-added product, second only to hyaluronic acid, and aims for further expansion of its business for medical institutions through domestic approval acquisition.

---

■ Details of the Business Consignment

Based on this agreement, CM Plus will provide the following support:

• Organization of basic information on the preparation

• Feasibility assessment of regulatory strategy

• Quality (CMC) evaluation

• Clinical package evaluation

• GMP, supply, and legal risk assessment

• Proposal of recommended application strategy

This will enable early visualization of key issues for approval acquisition, improving the accuracy and speed of application preparation.

---

■ Future Schedule

• April 2026: Business consignment agreement conclusion (planned)

• July 2026: Business commencement (planned)

• August 2026: Approval application (planned)

*The business commencement is premised on the establishment of a domestic sales system with a pharmaceutical company in Japan.

---

■ Future Outlook

While the impact of this agreement on current period performance is minor, in the medium to long term, the expansion of sales after approval acquisition could significantly affect our group's performance.

Specifically, the expansion of sales channels utilizing the existing network for aesthetic medical clinics and the advancement of cross-selling are expected to create continuous revenue opportunities.

---

■ Company Overview

About CONVANO Co., Ltd.

...